Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REMEDENT, INC. (REMI)
|
Add to portfolio |
|
|
|
| Price: |
$0.17
| | Metrics |
| OS: |
20.0
|
M
| |
|
|
| Market cap: |
$3.42
|
M
| |
|
|
|
Net cash:
|
$83.3
|
k
| |
$0.00
|
per share
|
|
EV:
|
$3.34
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($595.4)
|
k
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-20 | Mar-31-19 | Mar-31-18 | Mar-31-17 | Mar-31-16 | Mar-31-15 | Mar-31-14 | Mar-31-13 |
| Revenues | 1.1 | 1.6 | 2.7 | 2.4 | 2.8 | 3.6 | 2.6 | 2.9 |
| Revenue growth | -33.6% | -40.6% | 14.6% | -15.0% | -23.4% | 39.5% | -11.7% | -69.7% |
| Cost of goods sold | 0.3 | 0.5 | 0.9 | 1.2 | 0.8 | 1.3 | 1.0 | 1.4 |
| Gross profit | 0.7 | 1.1 | 1.8 | 1.2 | 2.0 | 2.3 | 1.6 | 1.5 |
| Gross margin | 69.7% | 69.7% | 66.0% | 50.3% | 70.5% | 64.6% | 62.8% | 51.2% |
| Sales and marketing | 0.4 | 0.7 | 0.9 | 0.6 | 0.5 | 0.8 | 0.7 | 0.8 |
| Research and development | | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| General and administrative | 0.7 | 1.0 | 1.1 | 1.4 | 1.3 | 1.2 | 1.4 | 2.2 |
| EBIT | -0.8 | 2.1 | 0.0 | -0.7 | 0.3 | 0.2 | -0.6 | -1.6 |
| EBIT margin | -78.3% | 133.1% | -1.0% | -31.1% | 9.8% | 5.9% | -22.4% | -54.9% |
| Pre-tax income | -0.9 | 2.1 | 0.0 | 0.8 | 0.2 | 0.2 | 0.5 | -1.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | | | 11.5% | 18.6% | 0.0% | |
| Net income | -0.9 | 2.1 | -0.1 | 0.8 | 0.2 | 0.1 | 0.5 | -1.0 |
| Net margin | -80.6% | 132.7% | -2.0% | 35.8% | 5.8% | 2.9% | 20.2% | -33.4% |
| |
| Diluted EPS | ($0.04) | $0.11 | $0.00 | $0.04 | $0.01 | $0.01 | $0.03 | ($0.05) |
| Shares outstanding (diluted) | 20.0 | 20.0 | 20.0 | 20.0 | 20.0 | 20.0 | 20.0 | 20.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|